Shop

Showing 865–880 of 1289 results

Article: Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant
€3.03 Add to cart
Article: Novel, rationally designed combination strategies, based on (phospho)-proteomic analyses, to enhance the response to cetuximab therapy in head and neck cancer
€3.03 Add to cart
Article: O.01 Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer
€3.03 Add to cart
Article: O.01 IDENTIFICATION, CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) MUTATIONS IN METASTATIC BREAST CANCER PATIENTS
€3.03 Add to cart
Article: O.02 Immuno-FIELT: The role of Tumor Infiltrating Lymphocytes and PD-L1 expression in NSCLC adenocarcinoma in little to non-smokers and its relationship with driver mutations and clinical outcome parameters
€3.03 Add to cart
Article: O.02 REAL-LIFE TREATMENT PRACTICE FOR MALIGNANT PLEURAL MESOTHELIOMA IN BELGIUM
€3.03 Add to cart
Article: O.03 DETECTION OF AR PERTURBATIONS IN CIRCULATING TUMOUR CELLS AND CELL-FREE DNA FROM PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREDICTS RESISTANCE TO ENDOCRINE THERAPY
€3.03 Add to cart
Article: O.03 Identification of candidate breast cancer predisposition genes by sequencing extended panel of 492 cancer associated genes in BRCA1/2 negative probands
€3.03 Add to cart
Article: O.04 PLOCABULIN, A TUBULIN INHIBITOR, HAS ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF GASTROINTESTINAL STROMAL TUMOR (GIST)
€3.03 Add to cart
Article: O.04 Type II RAF inhibition causes superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer
€3.03 Add to cart
Article: O.05 Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial
€3.03 Add to cart
Article: O.05 MT4-MMP, EGFR AND RB EXPRESSIONS ARE PREDICTIVE BIOMARKERS OF RESPONSE TO ERLOTINIB-PALBOCICLIB COMBINATION IN TRIPLE NEGATIVE BREAST CANCERS
€3.03 Add to cart
Article: O.06 PHOTOBIOMODULATION THERAPY FOR THE PREVENTION OF ACUTE RADIATION DERMATITIS: PRELIMINARY RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN BREAST CANCER PATIENTS
€3.03 Add to cart
Article: O.07 EFFECT OF MINDFULNESS TRAINING ON QUALITY OF LIFE AND DISTRESS IN CANCER PATIENTS
€3.03 Add to cart
Article: O.07 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth Patterns
€3.03 Add to cart
Article: O.08 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISH
€3.03 Add to cart

Article: Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant

Article: Novel, rationally designed combination strategies, based on (phospho)-proteomic analyses, to enhance the response to cetuximab therapy in head and neck cancer

Article: O.01 Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer

Article: O.01 IDENTIFICATION, CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) MUTATIONS IN METASTATIC BREAST CANCER PATIENTS

Article: O.02 Immuno-FIELT: The role of Tumor Infiltrating Lymphocytes and PD-L1 expression in NSCLC adenocarcinoma in little to non-smokers and its relationship with driver mutations and clinical outcome parameters

Article: O.02 REAL-LIFE TREATMENT PRACTICE FOR MALIGNANT PLEURAL MESOTHELIOMA IN BELGIUM

Article: O.03 DETECTION OF AR PERTURBATIONS IN CIRCULATING TUMOUR CELLS AND CELL-FREE DNA FROM PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREDICTS RESISTANCE TO ENDOCRINE THERAPY

Article: O.03 Identification of candidate breast cancer predisposition genes by sequencing extended panel of 492 cancer associated genes in BRCA1/2 negative probands

Article: O.04 PLOCABULIN, A TUBULIN INHIBITOR, HAS ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF GASTROINTESTINAL STROMAL TUMOR (GIST)

Article: O.04 Type II RAF inhibition causes superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer

Article: O.05 Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

Article: O.05 MT4-MMP, EGFR AND RB EXPRESSIONS ARE PREDICTIVE BIOMARKERS OF RESPONSE TO ERLOTINIB-PALBOCICLIB COMBINATION IN TRIPLE NEGATIVE BREAST CANCERS

Article: O.06 PHOTOBIOMODULATION THERAPY FOR THE PREVENTION OF ACUTE RADIATION DERMATITIS: PRELIMINARY RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN BREAST CANCER PATIENTS

Article: O.07 EFFECT OF MINDFULNESS TRAINING ON QUALITY OF LIFE AND DISTRESS IN CANCER PATIENTS

Article: O.07 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth Patterns

Article: O.08 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISH